BY 2025, TO BUILD 8 REGIONS FOR SUSTAINABLE EXPLOITATION OF NATURAL MEDICINAL MATERIALS
The Decision No. 376/QD-TTg approving the Program on development the pharmaceutical industry and domestically produced medicinal materials to 2030, with a vision to 2045 is issued on March 17, 2021 by the Prime Minister.
Accordingly, by 2025, domestically produced drugs will account for 75% of the used quantity and 60% of the market value, the rate of using medicinal materials of domestic origin and drugs from domestic medicinal materials will increase at least 10% over 2020.
The Program also aims to build 08 regions for sustainable exploitation of natural medicinal materials by 2025. To build 02 - 05 large-scale medicinal plant growing areas, each exploiting area or growing area having 01 - 02 chains of research, growing, processing and production of medicinal materials in compliance with the World Health Organization’s principles.
In order to achieve the above-mentioned targets, special incentives shall be applied to the research, transfer, and production of drug materials, especially drug materials of biological origin, and drug materials using domestic medicinal materials of high economic value.
Concurrently, investing in building and implementing the Center for Bioequivalence Testing and Clinical Testing, the Center for High-Tech Drugs, Drugs from Medicinal Materials and Traditional Drugs, and National Center for Research in Genetic Resources and Medicinal Material Seeds.
